A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)

Trial Profile

A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-659
  • Sponsors Merck Sharp & Dohme; Taiho Pharmaceutical Company
  • Most Recent Events

    • 05 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 07 Mar 2018 Planned initiation date changed from 2 Mar 2018 to 28 Mar 2018.
    • 16 Feb 2018 Planned End Date changed from 31 Dec 2020 to 17 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top